Ask AI

Unlocking the Full Potential of PROTAC ER Degraders in ER+/HER2- MBC: Novel Mechanisms, Testing Applications, and Data Insights to Address Unmet Needs

Enhance your ability to apply expert-guided treatment strategies for integrating PROTAC ER degraders into clinical practice based on current and emerging data supporting their use in patients with endocrine-resistant ER-positive/HER2-negative metastatic breast cancer through a certified text module, video modules, ClinicalThought commentaries, and accompanying downloadable slides.

Share

Program Content

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Pfizer, Inc. and Arvinas.

Arvinas

Pfizer, Inc.